Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Another little one…
Whatever own brand Vitamin D stock Boots bought has sold out online. “New stock coming soon”. We don’t know, of course, how much they bought initially, but it’s still a good sign I think.
If Chris hand will is maybe looking for a capital exit but at what price would tempt him ?
Just a bit of a throw away observation, but I did notice in the FOFH RNS that ABDX highlighted they will have rights to offer the STI tests as own brand retailer products, and you have to wonder if they have Boots in mind. Whatever the case, its clear that retailer own branding is something ABDX are pursuing and, of course, we can offer exactly the same test ( I think) to multiple retailers as an own brand product.
Lol, so glad I'm on your team, Muck. I'm going to make a pretty decent profit here because I now think I know all there is to know about this investment. You're a God-send. Have a great day!
In that vein, and to give a flavour, BBI were sold in 2021 for £400m.
Should be remembered that they provide antibodies, antigens, labels, and complementary reagents, as well as do everything ABDX does. But still…..
https://www.prnewswire.com/news-releases/novo-holdings-acquires-bbi-group-301312183.html#:~:text=COPENHAGEN%2C%20Denmark%2C%20June%2015%2C,value%20of%20over%20GBP%20400
Well said, and in fewer words than I normally manage! Maybe I should try the wine.
Longer term, well more medium term I think, I expect that Chris Hand will be looking for a capital exit. He’s already built, AIM listed and then sold one drugs of abuse LFT diagnostics company (Cozart, now part of Abbot) for £65m, and he must be looking at ABDX as his juicy retirement fund. He’s 63 next month.
It's all quite extraordinary really. I have to pinch myself at such a find. You once worried about the "sexiness" of what they have to offer, but for me, its the solidity, quality, vision and potential for growth that is most exciting. We can all latch onto the latest hype-driven trend and watch stocks rise, drop or even fall by the wayside, but IMO this is a company that will stay the distance and prosper and I think 78p in the nearish future is more than likely. Sex appeal works, business brains are better! (Been on the wine again!)
For awareness btw, there is a company called AbcDx that are trying to do exactly what Upfront are. They are being assisted by BBI (one of our major competitors), but seem to me to be AT LEAST 6 months behind Upfront.
https://www.abcdx.ch/solution/lvocheck
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1327348/full
TBH I think one advantage here is that unlike many other stocks, we’re not waiting on a single catalyst but instead have our fingers in so many pies. At the moment I’m watching out for any news on;
Septiloop sales/take up.
Salistick launch in new territories and possibly FDA authorisation. Equally any new U.K. retailers
Upfront funding and UKCA
Another own label Boots product(s)
News on EcoFlo pro type testing/results and possible commercial launch
And this is all just what’s on my radar for Q2/3, and ignores 52North, FOFH, and any other surprises we know nothing about.
I never put too much store in analyst predictions but 78p really doesn’t sound ridiculous to me as a 12 month target. If we were to do it though, the beauty is that it should be founded on solid year on year annuity income.
And as I’ve said before, our risk is spread widely across customers who have all spent years getting to where they are, and who therefore have every incentive to achieve commercial success.
Wow Muck, that sounds like a huge catalyst for the raise in share price we are all expecting.Im really looking forward to the trading results for the rest of this year. The market can't ignore us for much longer.
Another observation, this time just a post from Upfront.
https://www.linkedin.com/posts/upfrontdiagnostics_timeislife-activity-7188440790136676352-hZJU?utm_source=share&utm_medium=member_desktop
Upfront have been working with North East NHS Hospitals since 2018 and, as you can see from the post, that means they have built a product that not only works, but has been made specifically for use in the NHS. Its little wonder they were selected for the IDAP scheme and their LVOne test is, for my money, destined for widespread NHS adoption. The next I think we will hear from Upfront, which I suspect will come pretty shortly, is a successful latest funding round. Then it will be UKCA this quarter and then very quick NHS adoption and ergo manufacturing requirements.
Worth noting again that Upfront have been telling people that they can manufacture at scale. Well, we are their only manufacturing partner as far as I can tell.
Another observation…
It would appear that Salignostics have become a client of Sheng Enterprises, a Chinese company helping Israeli companies get a foothold in the Chinese market. More detail can be found here under the March 24 event “ The Israel Medical Device Special Matchmaking Event” - https://www.sheng-cn.com.cn/events-meetings/.
More on Sheng generally here - https://www.sheng-cn.com.cn/
More for awareness really
Been showing rapid growth in recent years and been stuck at 10p for a while buying pressure in recent weeks should eventually win a push this upto 20p hoping this week will be the week for that
Just another little observation….
ABDX latest blog was about security of supply chain, written by our COO Mark Jones - https://www.abingdonhealth.com/ensuring-your-critical-components-are-protected-the-importance-of-supply-agreements/
Whist this is undated, it appears to me to be a new news release from a company called Rosti, who have partnered with is for injection moulding.
https://rosti.com/rosti-uk-secures-exciting-new-project-with-abingdon-health/
Just interesting that focus lately has been on supply and security of manufacturing components.
I see Wynbore is still trying to get a foothold..
Set your phasers to stun lol
Goodness, springing upwards week by week. Won't be long now!
In that case we need to get 80p...... so £8m-12m profit to support that price, I guess.
12 months ... (maybe....) :0))
(Just my opinion DYOR etc)
Wyndrum, IIs won't even glance at a stock unless it has a mcap of > £100 mill as there just isn't enough liquidity for their size of dealing.
Hi Muck, yes it all looks to be coming together, and although at the moment, I can't see what the valuation could be, it would seem to be at a substantial premium to where it is now.
I think this is such a small cap that due to its size it HAS to go under the radar of ii's but with a couple more promising RNS's confirming extra sales order/contracts in effect making no more cash raises likely, will cause a re-rate and then as the mkt cap increases so it will then creep on to more analysts spread sheets.
So I wait for the virtuous circle that I believe has actually started (as foretold by the charts! ha ha :0))
atb
Hi Wyn
Agree - getting regulatory approval is like wading through treacle and all sorts of extra requests can delay things. But the point still remains valid - it’s reasonable to think we’re entering a time window when a decision might be made.
And the Times of Israel quoted Krieff last month as saying Salistick is currently being “positioned” in the States.
How approval might directly affect ABDX I don’t know - we’re unlikely to be a US distributor (although that would be amazing!), but we will still be manufacturing.
Hi Muck,
fwiw, but AGL went through the FDA thing. I think (I empasize think), that the FDA have a 150 days also to ask more questions or get more info if they feel they need it, rather than just a 150 day dead line for a decision. If they do request more data or whatever I believe the clock is rest. Again from memory, AGL waited over a year over the 150d days before they eventually succeeded with FDA approval And to be fair it was during covid so there exceptional time delays on the part of the FDA as well, so who knows.....
Just another small observation…
We know that Salignostics got UKCA approval in March 23, and that they also have CE. We also know they had initial meetings with the FDA by at least November 21.
Now, I’m not entirely sure what FDA approval pathway they’d have to follow, and so what additional requirements the FDA might have over and above conformity assessments in the U.K/EU
What I do know is that for a De Novo application, being the pathway for a device with no existing substantial equivalent, the FDA aim to give a decision within 150 days of having all necessary information.
So if we got UKCA in March 23, I think it’s reasonable to think an FDA decision can’t be too far away (assuming there’s been no hiccups!)
You're great Muck165! You sure are helpful. Hope youre getting out in the fresh air too as this share will come good when it's ready IMO! Exciting stuff - and just so happy that if newcomers do actually check out the opinions of shareholders on this board, they will find the majority of posts are so positive and forward looking and, as a bonus, so civilised lol .
1. Boots have little pop up that tells you how many times an item has been viewed, and how many times its been added to basket in the last 24 hours. I've been watching this daily (sad I know) since our Vit D and Iron tests launched, and we are consistently ahead of the MHC equivalents, despite no price differential. Boots are selling between 25 and 50 of each product each day, online only.
Loop - - their CEO has been heavily publicising a speaking session he is delivering at the EIT Health Summit on 18-19 April. Perhaps we might get a UKCA announcement before then?
As I say, just little observations...